Literature DB >> 2478219

An integrin receptor on normal and thrombasthenic platelets that binds thrombospondin.

J Lawler1, R O Hynes.   

Abstract

The members of the integrin family of membrane glycoprotein heterodimer complexes function as cell surface receptors for adhesive proteins. We report here on the identification of two integrins on the surface of human platelets that bind to thrombospondin. When platelet membrane proteins are radiolabeled with 125I-lactoperoxidase, solubilized in n-octylglucoside, (Boehringer Mannheim Biochemicals, Indianapolis, IN), and applied to a column of thrombospondin-Sepharose, both complexes are bound to the column and specifically eluted with the peptide GRGDSP. One of these integrins, glycoprotein (GP) IIb-IIIa, appears to bind relatively weakly. The second integrin shares the same beta subunit (beta 3 or GPIIIa), but has a distinct alpha subunit that comigrates with the alpha subunit (alpha v) of the vitronectin receptor (VnR) on endothelial cells and reacts with a monoclonal antibody, LM142, which was raised against an integrin from M21 melanoma cells. The alpha v beta 3 integrin is present on a variety of cell types and appears to act as a receptor for thrombospondin on endothelial and smooth muscle cells. On endothelial and M21 melanoma cells this receptor is also involved in adhesion to fibrinogen, vitronectin, and von Willebrand factor (vWF). The alpha v beta 3 integrin is present at approximately equal levels on normal and thrombasthenic platelets, whereas levels of GPIIb-IIIa are greatly reduced on thrombasthenic platelets. The alpha v beta 3 integrin on thrombasthenic platelets also binds to thrombospondin-Sepharose and can be eluted with the peptide GRGDSP. These data indicate that the alpha v beta 3 integrin on platelets, endothelial cells, and smooth muscle cells functions as an Arg-Gly-Asp (RGD)-dependent receptor for thrombospondin.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2478219

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  48 in total

1.  Combined therapy with thrombospondin-1 type I repeats (3TSR) and chemotherapy induces regression and significantly improves survival in a preclinical model of advanced stage epithelial ovarian cancer.

Authors:  Samantha Russell; Mark Duquette; Joyce Liu; Ronny Drapkin; Jack Lawler; Jim Petrik
Journal:  FASEB J       Date:  2014-11-13       Impact factor: 5.191

Review 2.  Thrombospondin as a mediator of cancer cell adhesion in metastasis.

Authors:  D A Walz
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

3.  The evolution of thrombospondins and their ligand-binding activities.

Authors:  Amber A Bentley; Josephine C Adams
Journal:  Mol Biol Evol       Date:  2010-04-28       Impact factor: 16.240

4.  Neutrophil accumulation on activated, surface-adherent platelets in flow is mediated by interaction of Mac-1 with fibrinogen bound to alphaIIbbeta3 and stimulated by platelet-activating factor.

Authors:  C Weber; T A Springer
Journal:  J Clin Invest       Date:  1997-10-15       Impact factor: 14.808

Review 5.  Thrombospondins as key regulators of synaptogenesis in the central nervous system.

Authors:  W Christopher Risher; Cagla Eroglu
Journal:  Matrix Biol       Date:  2012-01-21       Impact factor: 11.583

6.  Shear stress induced release of von Willebrand factor and thrombospondin-1 in HUVEC extracellular matrix enhances breast tumour cell adhesion.

Authors:  Noëlia Gomes; Chantal Legrand; Françoise Fauvel-Lafève
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

Review 7.  Matricellular proteins in cardiac adaptation and disease.

Authors:  Nikolaos G Frangogiannis
Journal:  Physiol Rev       Date:  2012-04       Impact factor: 37.312

Review 8.  Structures of thrombospondins.

Authors:  C B Carlson; J Lawler; D F Mosher
Journal:  Cell Mol Life Sci       Date:  2008-03       Impact factor: 9.261

9.  Thrombospondin-1 controls vascular platelet recruitment and thrombus adherence in mice by protecting (sub)endothelial VWF from cleavage by ADAMTS13.

Authors:  Arnaud Bonnefoy; Kim Daenens; Hendrik B Feys; Rita De Vos; Petra Vandervoort; Jos Vermylen; Jack Lawler; Marc F Hoylaerts
Journal:  Blood       Date:  2005-10-04       Impact factor: 22.113

10.  The Most N-Terminal Region of THSD7A Is the Predominant Target for Autoimmunity in THSD7A-Associated Membranous Nephropathy.

Authors:  Larissa Seifert; Elion Hoxha; Anna M Eichhoff; Gunther Zahner; Silke Dehde; Linda Reinhard; Friedrich Koch-Nolte; Rolf A K Stahl; Nicola M Tomas
Journal:  J Am Soc Nephrol       Date:  2018-03-19       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.